104 results
Page 4 of 6
8-K
EX-99.6
7ag2qnx
4 Sep 12
Other Events
12:00am
8-K
EX-99.1
492ndz2
22 May 12
Other Events
12:00am
8-K
EX-99.3
8itt2h9aojf56
22 May 12
Other Events
12:00am
8-K
EX-99.2
fvi zel8ajlrkl
22 May 12
Other Events
12:00am
8-K
6ervy
22 May 12
Other Events
12:00am
8-K
EX-99.4
b7uw y84im56s5
22 May 12
Other Events
12:00am
8-K
EX-99
y4gimh lndb
26 Apr 12
Results of Operations and Financial Condition
12:00am
8-K
EX-99
99t5t2v
27 Oct 11
Results of Operations and Financial Condition
12:00am
8-K
ee0ailomi0b0xv9c nk8
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99.3
m8ohckhlju70tuy
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99.4
jgnkrt9orp8ebk
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99.2
qcqnmj
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99.1
s17ckubkd rcr
26 Sep 11
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation in COPD
12:00am
8-K
EX-99
2pbm3qe8bm8 dr5u1s
28 Jul 11
Results of Operations and Financial Condition
12:00am
8-K
mp07gexwkv l41lqa50
17 May 11
Dose-related efficacy and optimal once-daily dosing interval of the long-acting beta2
12:00am
8-K
EX-99.1
ddnf7
17 May 11
Dose-related efficacy and optimal once-daily dosing interval of the long-acting beta2
12:00am
8-K
EX-99
mrr7hvh4i2 7h07g
21 Oct 10
Results of Operations and Financial Condition
12:00am
8-K
EX-99
iihsuz529015bmh
22 Sep 10
Other Events
12:00am
8-K
6nm8km1f
22 Sep 10
Other Events
12:00am